Drugs / rhAnnexin V-128
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03232580 | Sep 2017 → Nov 2018 | spondyloarthropathy | Advanced Accelerator Applications | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhAnnexin V-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03232580 ↗ |
| Modality | Diagnostic / imaging agent | “investigational imaging agent 99mTc-rhAnnexin V-128” NCT03232580 ↗ |
| Route | Intravenous | “single i.v injection” NCT03232580 ↗ |